Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content
Fig. 7 | The Journal of Headache and Pain

Fig. 7

From: Increased TSPO alleviates neuropathic pain by preventing pyroptosis via the AMPK-PGC-1α pathway

Fig. 7

Mitochondrial dysfunction was observed during pyroptosis induction in primary astrocytes. A Representative images of GFAP immunofluorescence staining to identify astrocytes, scale bar = 50 μm. B, C ELISA showing the levels of IL-1β and IL-18 in different groups, n = 6 per group. D Representative images of PI staining demonstrate the number of pyroptotic cells in the different groups, scale bar = 50 μm. E Western blot showing the expression levels of p-AMPK, PGC1, MFN2, and TFAM after ATP + LPS treatment. F Representative images of ROS staining indicate the level of ROS produced by astrocytes after ATP + LPS treatment, scale bar = 50 μm. G Representative images of MitoSOX staining show the level of mitochondrial ROS levels after ATP + LPS treatment, scale bar = 50 μm. H Representative images of JC-1 staining show a shift from aggregates (red) to monomers (green), indicating mitochondrial depolarization, scale bar = 50 μm. I Representative images of Mito-Tracker staining show mitochondrial morphology, scale bar = 20 μm. J Quantification of mitochondrial aspect ratio, n = 6 per group. K Western blot showing the expression levels of TSPO, NLRP3, Caspase-1, and GSDMD-N after ATP + LPS treatment. Data are represented as mean ± SEM, ***p < 0.001

Back to article page